Inosine
|
| Systematic (IUPAC) name |
| 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one |
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Pregnancy cat. |
? |
| Legal status |
OTC |
| Pharmacokinetic data |
| Metabolism |
Hepatic |
| Identifiers |
| CAS number |
58-63-9 Y |
| ATC code |
D06BB05 G01AX02 |
| PubChem |
CID 6021 |
| DrugBank |
DB04566 |
| ChemSpider |
5799 Y |
| UNII |
5A614L51CT Y |
| KEGG |
C00294 Y |
| ChEBI |
CHEBI:17596 Y |
| ChEMBL |
CHEMBL1556 N |
| Chemical data |
| Formula |
C10H12N4O5 |
| Mol. mass |
268.23 g/mol |
SMILES
- c1[nH]c2c(c(=O)n1)ncn2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
|
InChI
-
InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1 Y
Key:UGQMRVRMYYASKQ-KQYNXXCUSA-N Y
|
N (what is this?) (verify)
|
Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond.
Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.
Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase, yielding xanthosine monophosphate, a key precursor in purine metabolism. Mycophenolate mofetil is an anti-metabolite, anti-proliferative drug that acts as an inhibitor of inosine monophosphate dehydrogenase. It is used in the treatment of a variety of autoimmune diseases including Wegener's granulomatosis because the uptake of purine by actively dividing B cells can exceed 8 times that of normal body cells, and, therefore, this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from IMD inhibition.
|
Contents
- 1 Reactions
- 2 Clinical significance
- 3 Biotechnology
- 4 Fitness
- 5 Feeding Stimulant
- 6 See also
- 7 References
- 8 External links
|
Reactions [edit]
Adenine is converted to adenosine or inosine monophosphate (IMP), either of which, in turn, is converted into inosine (I), which pairs with Adenine (A), cytosine (C), and uracil (U).
Purine nucleoside phosphorylase intraconverts inosine and hypoxanthine.
Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.
Clinical significance [edit]
It was tried in the 1970s in Eastern countries for improving athletic performance. Nevertheless, the clinical trials for this purpose showed no improvement.[1] It has been shown that inosine has neuroprotective properties. It has been proposed for spinal cord injury;[2] because it improves axonal rewiring, and for administration after stroke, because observation has shown that axonal re-wiring is encouraged.[3]
It is currently in phase II trials for multiple sclerosis (MS).[4] It produces uric acid after ingestion, which is a natural antioxidant and a peroxynitrite scavenger, which may suggest possible benefit in MS[5] (peroxynitrite has been correlated with axon degeneration [1]).
It is also in phase II trials for Parkinson's disease. Earlier trials had suggested those with the highest serum urate levels had lower progression of Parkinson's symptoms. The trial uses inosine to raise urate levels in those with levels lower than the population mean (6 mg/dL). [6] [7]
Alseres Pharmaceuticals (named Boston Life Sciences when patent was granted) patented the treatment for stroke [2] and is currently investigating the drug in the MS setting.[8]
In the Anatomical Therapeutic Chemical Classification System, it is classified as an antiviral.[9]
Biotechnology [edit]
When designing primers for polymerase chain reaction, inosine is useful in that it will indiscriminately pair with adenine, thymine, or cytosine. This allows for design of primers that span a single-nucleotide polymorphism, without the polymorphism disrupting the primer's annealing efficiency.
Fitness [edit]
Despite lack of clinical evidence that it improves muscle development, inosine remains an ingredient in some fitness supplements.
Feeding Stimulant [edit]
Inosine has also been found to be an important feed stimulant by itself or in combination with certain amino acids in some species of farmed fish. For example, inosine and inosine-5-monophosphate have been reported as specific feeding stimulants for turbot fry, (Scophthalmus maximus) [10] and yellowtail, (Seriola quinqueradiata).[11] The main problem of using inosine and/or inosine-5-monophosphate as feeding attractants is their high cost. However, their use may be economically justified within larval feeds for marine fish larvae during the early weaning period, since the total quantity of feed consumed is relatively low.
See also [edit]
- Inosine monophosphate dehydrogenase
- Nucleobase
References [edit]
- ^ McNaughton L, Dalton B, Tarr J (1999). "Inosine supplementation has no effect on aerobic or anaerobic cycling performance". International journal of sport nutrition 9 (4): 333–44. PMID 10660865.
- ^ Liu F, You SW, Yao LP et al. (2006). "Secondary degeneration reduced by inosine after spinal cord injury in rats". Spinal Cord 44 (7): 421–6. doi:10.1038/sj.sc.3101878. PMID 16317421.
- ^ Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI (2002). "Inosine induces axonal rewiring and improves behavioral outcome after stroke". Proc. Natl. Acad. Sci. U.S.A. 99 (13): 9031–6. doi:10.1073/pnas.132076299. PMC 124418. PMID 12084941.
- ^ Treatment of Multiple Sclerosis Using Over the Counter Inosine - Full Text View - ClinicalTrials.gov
- ^ Uric Acid: Natural Scavenger Of Peroxynitrite
- ^ "Safety of Urate Elevation in Parkinson's Disease".
- ^ "Safety of Urate Elevation in Parkinson's Disease". ClinicalTrials.gov.
- ^ Alseres pharma drug description
- ^ "ATC/DDD Index".
- ^ Mackie, A.M. (1987). Identification of the gustatory feeding stimulants. In: Chemoreception in Fishes. (ed. T.J. Hara). Elsevier Scientific Publishing Co., Amsterdam, pp. 275-291.
- ^ Takeda, M. Takii, K. & Matsui, K. (1984). Identification of feeding stimulants for juvenile eel. Bull. Jap. Soc. Scient. Fish., 50: 645-651.
External links [edit]
|
Antibiotics and chemotherapeutics for dermatological use (D06)
|
|
| Antibiotics |
|
Tetracycline and derivatives
|
- Demeclocycline
- Chlortetracycline
- Oxytetracycline
- Tetracycline
|
|
|
Others
|
- Amphenicol: Chloramphenicol
- Aminoglycosides: Neomycin
- Gentamicin
- Amikacin
- Streptogramin: Virginiamycin
- other: Fusidic acid
- Bacitracin
- Tyrothricin
- Mupirocin
|
|
|
| Chemotherapeutics |
|
Sulfonamides
|
- Silver sulfadiazine
- Sulfathiazole
- Mafenide
- Sulfamethizole
- Sulfanilamide
- Sulfamerazine
|
|
|
Antivirals
|
- Aciclovir
- Penciclovir
- Idoxuridine
- Edoxudine
- Imiquimod/Resiquimod
- Podophyllotoxin
Docosanol
- Tromantadine
- Inosine
- Lysozyme
- Ibacitabine
|
|
|
Other
|
- Ingenol mebutate
- Metronidazole
|
|
|
|
|
|
noco (i/b/d/q/u/r/p/m/k/v/f)/cong/tumr (n/e/d), sysi/epon
|
proc, drug (D2/3/4/5/8/11)
|
|
|
|
|
Gynecological anti-infectives and antiseptics (G01)
|
|
| Antibiotics |
- Candicidin
- Chloramphenicol
- Hachimycin
- Oxytetracycline
- Carfecillin
- Mepartricin
- Clindamycin
- Pentamycin
|
|
| Arsenic compounds |
|
|
| Quinoline derivatives |
- Diiodohydroxyquinoline
- Clioquinol
- Chlorquinaldol
- Dequalinium
- Broxyquinoline
- Oxyquinoline
|
|
| Organic acids |
- Lactic acid
- Acetic acid
- Ascorbic acid
|
|
| Sulfonamides |
|
|
| Antifungals |
|
Imidazoles
|
- Metronidazole
- Clotrimazole
- Miconazole
- Econazole
- Ornidazole
- Isoconazole
- Tioconazole
- Ketoconazole
- Fenticonazole
- Azanidazole
- Propenidazole
- Butoconazole
- Omoconazole
- Oxiconazole
- Flutrimazole
|
|
|
Triazoles
|
|
|
|
Polyenes
|
- Nystatin
- Natamycin
- Amphotericin B
|
|
|
Other
|
- Ciclopirox
- Methylrosaniline
|
|
|
| Other |
- Clodantoin
- Inosine
- Policresulen
- Nifuratel
- Furazolidone
- Povidone-iodine
- Protiofate
- Lactobacillus fermentum
- Copper usnate
|
|
|
|
|
noco/cong/npls, sysi/epon
|
proc/asst, drug (G1/G2B/G3CD)
|
|
|
|
|
DNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
| Baltimore I |
|
Herpesvirus
|
|
DNA-synthesis
inhibitor
|
|
TK activated
|
|
Purine analogue
|
- guanine (Aciclovir#/Valacyclovir
- Ganciclovir/Valganciclovir
- Penciclovir/Famciclovir)
|
|
|
Pyrimidine analogue
|
- uridine (Idoxuridine
- Trifluridine
- Edoxudine)
|
|
|
|
Not TK activated
|
|
|
|
|
Other
|
- Docosanol
- early protein (Fomivirsen)
- Tromantadine
|
|
|
|
HPV/MC
|
- Imiquimod/Resiquimod
- Podophyllotoxin
|
|
|
Vaccinia
|
|
|
|
Poxviridae
|
|
|
|
| Hepatitis B (VII) |
- Nucleoside analogues/NARTIs: Entecavir
- Lamivudine
- Telbivudine
- Clevudine
- Nucleotide analogues/NtRTIs: Adefovir
- Tenofovir
|
|
| Multiple/general |
|
Nucleic acid inhibitors
|
|
|
|
Interferon
|
- Interferon alfa-2b
- Peginterferon alfa-2a
|
|
|
Multiple/unknown
|
- Ribavirin#/Taribavirin†
- Moroxydine
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drug (dnaa, rnaa, rtva, vacc)
|
|
|
|
